Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Metabolic dysfunction-associated steatotic liver disease and the heart
Stan Driessen, Sven Francque, Stefan D. Anker, et al.
Hepatology (2023)
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Steatotic liver disease
Mads Israelsen, Sven Francque, Emmanuel Tsochatzis, et al.
The Lancet (2024) Vol. 404, Iss. 10464, pp. 1761-1778
Closed Access | Times Cited: 24
Pravastatin reduces all-cause mortality in elderly at risk of liver fibrosis: post-hoc analysis of the PROSPER trial
Vivian D. de Jong, Willy Theel, Manuel Castro Cabezas, et al.
JHEP Reports (2025), pp. 101337-101337
Open Access | Times Cited: 1
Associations between estimated glucose disposal rate and arterial stiffness and mortality among US adults with non-alcoholic fatty liver disease
Junting Song, Ruicong Ma, Lin Yin
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 10
2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes
Amélio F. Godoy‐Matos, Cynthia Melissa Valério, Wellington S. Silva Júnior, et al.
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 8
Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact
Anna Alisi, Geoffrey W. McCaughan, Henning Grønbæk
Hepatology International (2024) Vol. 18, Iss. S2, pp. 861-872
Closed Access | Times Cited: 7
Perspective article: determinants and assessment of cardiovascular risk in steatotic liver disease owing to metabolic dysfunction-addressing the challenge
Mohamad Jamalinia, Amedeo Lonardo
Metabolism and Target Organ Damage (2024) Vol. 4, Iss. 3
Open Access | Times Cited: 5
Randomised double-blind placebo-controlled trial protocol to evaluate the therapeutic efficacy of lyophilised faecal microbiota capsules amended with next-generation beneficial bacteria in individuals with metabolic dysfunction-associated steatohepatitis
Quinten J. J. Augustijn, Aldo Grefhorst, Pleun de Groen, et al.
BMJ Open (2025) Vol. 15, Iss. 1, pp. e088290-e088290
Open Access
Tanshinone IIA alleviate atherosclerosis and hepatic steatosis via down-regulation of MAPKs/NF-κB signaling pathway
Yifan Zhang, Jiarou Wang, Shuo Yang, et al.
International Immunopharmacology (2025) Vol. 152, pp. 114465-114465
Closed Access
Dietary Determinants of Metabolic Syndrome: Focus on the Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Manish Verma, Madhulika Tripathi, Brijesh Kumar Singh
IntechOpen eBooks (2024)
Open Access | Times Cited: 4
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development
Farah Khaznadar, Omar Khaznadar, Ana G. Petrovic, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 7, pp. 6300-6314
Open Access | Times Cited: 4
Association between cardiovascular health and metabolic dysfunction-associated steatotic liver disease: a nationwide cross-sectional study
Lian-Zhen Huang, Zi-Wei Ni, Wei-Feng Huang, et al.
Journal of Health Population and Nutrition (2025) Vol. 44, Iss. 1
Open Access
MASH to cirrhosis: bridging the gaps in MASLD management
Zouhir Gadi, Wilhelmus J. Kwanten, Luisa Vonghia, et al.
Acta Clinica Belgica (2025), pp. 1-10
Closed Access
Cross-sectional study on the association between the fibrosis-4 index and co-occurring myocardial infarction in Chinese patients with type 2 diabetes mellitus
Ziyi Sun, Jin Zhang, Jinlong Duan, et al.
Frontiers in Endocrinology (2025) Vol. 16
Open Access
Druggable genome-wide Mendelian randomization identifies therapeutic targets for metabolic dysfunction-associated steatotic liver disease
Xiaohui Ma, Li Ding, Shuo Li, et al.
Lipids in Health and Disease (2025) Vol. 24, Iss. 1
Open Access
Prevalence of metabolic dysfunction-associated steatotic liver disease and steatohepatitis in Türkiye: A forensic autopsy study
İlkay Ergenç, Erdoğan Kara, Muhammed Emre Yilmaz, et al.
Heliyon (2024) Vol. 10, Iss. 15, pp. e34915-e34915
Open Access | Times Cited: 3
Extraction of polysaccharides from Polygonum cuspidatum with activity against Type 2 Diabetes via alterations in gut microbiota
Zhiqiang Zhang, Jin-Yang Lai, Xilin Fan, et al.
Food Chemistry (2024) Vol. 470, pp. 140047-140047
Closed Access | Times Cited: 2
Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease
Jacob J. Gries, Jeffrey V. Lazarus, Paul Brennan, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 10, Iss. 1, pp. 82-94
Closed Access | Times Cited: 2
LRP1 facilitates hepatic glycogenesis by improving the insulin signaling pathway in HFD‐fed mice
Xingxian Guo, Jiangxia Pu, Ziqi Tang, et al.
Animal Models and Experimental Medicine (2024)
Open Access | Times Cited: 1
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development
Farah Khaznadar, Omar Khaznadar, Ana G. Petrovic, et al.
(2024)
Open Access | Times Cited: 1
Cell-specific regulation of insulin action and hepatic fibrosis by CEACAM1
Basel Aldroubi, John Najjar, Tya S Youssef, et al.
Metabolism and Target Organ Damage (2024) Vol. 4, Iss. 4
Open Access | Times Cited: 1
Association of fatty liver index with sudden cardiac arrest in young adults
Joo Hee Jeong, Yun Gi Kim, Kyungdo Han, et al.
Metabolism (2024) Vol. 158, pp. 155981-155981
Closed Access
Genetic associations of birthweight, childhood, and adult BMI with metabolic dysfunction-associated steatotic liver disease: a Mendelian randomization
Xiaohui Ma, Lina Chang, Shuo Li, et al.
BMC Gastroenterology (2024) Vol. 24, Iss. 1
Open Access
Chinese herbal formula in the treatment of metabolic dysfunction-associated steatotic liver disease: current evidence and practice
Shaohong Tao, Yu‐Qing Lei, Yimei Tan, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access
Role of metabolic dysfunction-associated steatotic liver disease and of its genetics on kidney function in childhood obesity
Anna Di Sessa, Sarah Zarrilli, Gabriele Forcina, et al.
International Journal of Obesity (2024)
Closed Access
Associations between MASLD, atrial fibrillation, cardiovascular events, mortality and aspirin use in older adults
Daniel Clayton‐Chubb, Stuart K. Roberts, Ammar Majeed, et al.
GeroScience (2024)
Closed Access
Page 1 - Next Page

Scroll to top